Cronos News
Altria Group, Inc Conference Call
A replay of the conference call will be available for approximately two weeks, from December 7, 2018 through December 21, 2018, and can be accessed by dialing (855) 859-2056 and providing the 9359909 confirmation code.
Toll-free dial-in number: (855) 859-2056
Passcode: 9359909
Altria Group, Inc Conference Call
A replay of the conference call will be available for approximately two weeks, from December 7, 2018 through December 21, 2018, and can be accessed by dialing (855) 859-2056 and providing the 9359909 confirmation code.
Toll-free dial-in number: (855) 859-2056
Passcode: 9359909
Cronos Group Inc. Announces Mailing of Meeting Materials in Connection with Upcoming Special Meeting of Shareholders
Cronos Group Inc. is pleased to announce that the meeting materials for a special meeting of holders of common shares of the Company to be held on February 21, 2019, including the management proxy circular dated December 31, 2018, prepared in connection with the proposed C$2.4 billion equity investment by Altria Group, Inc. in Cronos Group previously announced on December 7, 2018, have been mailed to Shareholders and filed with the relevant Canadian securities regulators.
read moreCronos Group Inc. Announces C$2.4 Billion Strategic Investment from Altria Group, Inc
Cronos Group Inc. today announced that it has entered into a subscription agreement with Altria Group, Inc. pursuant to which Altria has agreed to make an approximately C$2.4 billion equity investment in Cronos Group on a private placement basis in exchange for common shares in the capital of the Company. Altria will also receive Warrants of Cronos Group, that if fully exercised, would provide the Company with an additional approximately C$1.4 billion of proceeds. The Shares issuable to Altria pursuant to the Subscription Agreement will result in Altria holding an approximately 45% ownership interest in Cronos Group (calculated on a non-diluted basis), exercise of the Warrants would result in incremental ownership of 10% for a total potential ownership position of 55%. This strategic partnership provides Cronos Group with additional financial resources, product development and commercialization capabilities, and deep regulatory expertise to better position the Company to compete, scale and lead the rapidly growing global cannabis industry.
read moreCronos Group Confirms Discussions Regarding Potential Investment by Altria Group
Cronos Group Inc. today confirmed that it is engaged in discussions concerning a potential investment by Altria Group Inc. in Cronos Group. No agreement has been reached with respect to any such transaction and there can be no assurance such discussions will lead to an investment or other transaction involving the companies.
read moreCronos Group Inc. Announces Third Quarter 2018 Results
“We are encouraged with our third quarter results, which reflect the meaningful progress we are making on our strategic initiatives. In the quarter, we announced a number of landmark partnerships to expand our reach beyond the flower and beyond Canada and launched our second differentiated recreational cannabis brand,” said Mike Gorenstein, CEO of Cronos Group.
read moreCronos Group Inc. to Hold Third Quarter 2018 Earnings Conference Call
Cronos Group, a geographically diversified and vertically integrated cannabis group, will announce its financial results and hold its Third Quarter 2018 Earnings Conference Call on Tuesday, November 13, 2018 at 8:30 a.m. EDT. Senior management will be available for questions from the investment community after prepared remarks.
read moreCanada Makes History and Cronos Group Inc. Looks Forward with Enthusiasm
Today, Canada became the first G7 country and the second country in the world to legalize cannabis sales for adult recreational use.
read moreCronos Group Inc. Partners with Technion Research & Development Foundation for Cannabinoid-Based Skin Care Treatments
Cronos Group Inc. Partners with Technion Research & Development Foundation for Cannabinoid-Based Skin Care Treatments.
read moreAleafia Partners with Cronos Group on Medical Cannabis Sleep Study
The study is funded in part by Peace Naturals Project Inc., a licensed producer of medical cannabis that is wholly owned by Cronos Group. The study will be led by physicians practicing within the Canabo Medical Clinic network, which is wholly owned by Aleafia.
read moreCronos Group Inc. Launches New Recreational Brand Spinach
Spinach™ is focused on offering Farm-To-Bowl™ products that bring friends together and make experiences more enjoyable. Spinach™ has selected some of the most popular strains from Cronos Group’s genetic library because when you’re having fun, you should never have to worry about the quality of your Spinach™. Harmful additives don’t have a place in good Spinach™, which is why quality control is the only think we take seriously. More information on how to Get-Your-Greens™ can be found at www.spinachcannabis.com. Warning: Spinach™ may be a gateway to pizza
read moreA Landmark Partnership to Produce Cultured Cannabinoids
Leading Companies from Emerging Industries Join Forces to Efficiently Produce High-Purity Cannabinoids at Scale.
Today, Cronos Group Inc. and Ginkgo Bioworks Inc. announced a landmark partnership to produce cultured cannabinoids. Using its platform technology for organism design and development, Ginkgo will complement Cronos Group’s technologies for producing a full spectrum of cannabinoids. As part of this unprecedented deal, Cronos Group has agreed to issue a specific number of common shares in tranches subject to Ginkgo’s achievement of certain production milestones.
Cronos Group Inc. Unveils Platform in LATAM
Cronos Group Inc., is pleased to announce that it has entered into a joint venture agreement with an affiliate of Agroidea SAS (“AGI”), Colombia’s leading agricultural services provider with over 30 years of research, development and production operations. This partnership establishes a newly formed entity, NatuEra S.à r.l. (“NatuEra”), in Colombia that will develop, cultivate, manufacture and export cannabis-based medicinal and consumer products for the Latin American and global markets.
read moreCronos Group Inc. Announces Provincial Supply Agreements
Cronos Group has secured listings and signed binding master supply agreements with both the Ontario Cannabis Retail Corporation and the BC Liquor Distribution Branch. In combination, these provinces encompass over 50% of the Canadian population and hence the potential customer base which the Company is prepared to serve.
read moreCronos Group Inc. Announces Second Quarter 2018 Results
“This year and subsequently, this quarter is about setting the stage and establishing Cronos Group’s strategy for future growth,” said Mike Gorenstein, CEO of Cronos Group. “Cronos Group delivered encouraging results across the Company in the second quarter with sales growing among all of our products and channels, impressive improvements in cultivation yields since the start of the year, and continued business development success in penetrating new markets and establishing new partnerships for expansion.”
read moreCura Goes International with Cronos Group Inc.
Cronos Group Inc., is pleased to announce that it has entered into a supply agreement with one of the largest cannabis companies in the world by revenue in the first quarter of 2018, Cura Select Canada, Ltd. Cura is on a mission to be the leading provider of premium cannabis oil and hemp oil to the legal U.S. and international markets, and will enter the Canadian market to supply domestic and international channels.
read moreCronos Group Inc. Announces Capacity Expansion with Premier Greenhouse Expert
Cronos Group Inc., is pleased to announce that it has entered into a joint venture partnership with a group of investors led by Bert Mucci (the “Greenhouse Partners”), one of Canada’s most sophisticated greenhouse operators and builders.
read moreCronos Group Inc. to Hold Second Quarter 2018 Earnings Conference Call
Cronos Group Inc., a geographically diversified and vertically integrated cannabis group, will announce its financial results and hold its Second Quarter 2018 Earnings Conference Call.
read moreCronos Group Inc. Announces Results of Vote for Election of Directors
(“Cronos Group” or the “Company”), a geographically diversified and vertically integrated cannabis group, reports that at its Annual and Special Meeting of Shareholders on June 28, 2018 there were 658 shareholders voting in person and by proxy holding in total 92,611,201 common shares, representing 52.56% of the total number of common shares outstanding.
read moreCronos Group Inc. Announces Exclusive Distribution Agreement with Delfarma in Poland
Cronos Group Inc., is pleased to announce that it has entered into a strategic distribution partnership with Delfarma Sp. Zo.o. Founded in 2004, Delfarma is a privately owned pharmaceutical wholesaler and was the first company in Poland to introduce international parallel import of medicinal products from European Economic Area countries.
read moreCronos Australia is Granted Manufacturing License
(“Cronos Group” or the “Company”), is pleased to announce that Cronos Australia Pty Ltd. (“Cronos Australia”) has been granted a medicinal cannabis Manufacture License by the Australian Office of Drug Control.
read moreCronos Group Inc. Sets Date for 2018 Annual and Special Meeting of Shareholders
Cronos Group Inc. will hold its 2018 Annual and Special Meeting of Shareholders on Thursday, June 28, 2018 at 9:30 a.m. at the offices of Blake, Cassels & Graydon LLP located at 199 Bay Street, Suite 4000, Commerce Court West, Toronto.
read moreCronos Group Inc. To Up List and Begin Trading on Toronto Stock Exchange
The Cronos Group Inc. is pleased to announce that trading of its common shares in Canada will be elevated from the TSX Venture Exchange (“TSX-V”) to the Toronto Stock Exchange (“TSX”).
read moreCronos Group Inc. Appoints Lead Director, Engages Investor Relations Agency and Grants Options
The Cronos Group Inc. announced today it has appointed Jim Rudyk as lead director and has entered into an engagement agreement to retain Athena Advisors LLC (“Athena Advisors”) as its agency of record for investor relations and corporate communications.
read moreCronos Group Inc. Announces First Quarter 2018 Results
Cronos Group Inc. today announced financial results for the first quarter ended March 31, 2018.
read moreCronos Group Inc. to Hold Conference Call on First Quarter 2018 Financial Results
Cronos Group Inc. will release its financial results for the first quarter ended March 31, 2018 before the market opens on May 15, 2018.
read moreCronos Group Inc. Announces Fourth Quarter and Fiscal Year 2017 Results
Cronos Group Inc. today announced financial results for the fourth quarter and fiscal year ended December 31, 2017.
“We are building Cronos Group with a focus on the long-term and 2017 set the foundation for the explosive growth we have already started realizing in 2018,” said Mike Gorenstein,” CEO of Cronos Group. “We are extremely proud of all that our team has accomplished and look forward to a year of rapid increases in sales, commencing distribution in new markets, further developing disruptive intellectual property and launching new iconic brands.”
Cronos Group Inc. to Hold Conference Call on Fourth Quarter and Fiscal Year 2017 Financial Results
TORONTO, April 27, 2018 /CNW/ – Cronos Group Inc. (NASDAQ, TSX-V: CRON) ("Cronos Group" or the "Company") will release its financial results for the fourth quarter and fiscal year ended December 31, 2017 before the market opens on April 30, 2018. Conference Call...
read moreCronos Group Announces Closing of Previously Announced $100 Million Bought Deal
Cronos Group is pleased to announce that it has closed its previously announced bought deal public offering. A total of 10,420,000 common shares of Cronos Group were sold at a price of $9.60 per Share for aggregate gross proceeds of approximately $100.0 million.
read moreCronos Group Inc. Announces $100 Million Bought Deal
Cronos Group is pleased to announce that it has entered into an agreement with a syndicate of underwriters co-led by GMP Securities L.P. and BMO Capital Markets to sell 10,420,000 common shares (11,983,000 common shares if the over-allotment described below is exercised in full) of the Company, on a “bought deal” basis, at a price of $9.60 per common share, for gross proceeds of approximately $100.0 million (approximately $115.0 million if the over-allotment option is exercised in full).
read moreCannabis Giants Join Forces in Cross Border Venture
With Canada on track to legalize adult use of cannabis, two of the world’s largest cannabis companies announced a first-of-its-kind cross border joint venture today that could bring America’s most recognized cannabis brand to Canadian consumers by year’s end.
read moreCronos Group Changes Canadian Ticker to CRON
Cronos Group Inc. is pleased to announce that the Company is changing its ticker on the TSX Venture Exchange from MJN to CRON. This change is effective immediately for trading commencing on Monday, March 5 and is being made to conform to the ticker symbol that was selected when Cronos Group became the first pure-play cannabis company to trade on the Nasdaq on February 27, 2018
read moreCronos Group to Begin Trading on NASDAQ Stock Exchange
Cronos Group Inc. (TSX-V: MJN) (OTC Nasdaq Int’l Designation: PRMCF) is pleased to announce that trading of its common shares in the United States will be elevated from the Nasdaq International Designation program to the Nasdaq Global Market. Cronos Group expects that its common shares will begin trading on Nasdaq on February 27, 2018 under the trading ticker symbol “CRON.” Cronos Group will retain its listing on the TSX Venture Exchange under the symbol “MJN.”
read moreCronos Group Announces Launch of Cronos Australia with Grant of Two Licenses
Cronos Australia is a 50/50 joint venture between the Group and NewSouthern Capital Pty Ltd, led by Mr. Rodney Cocks and Mr. Peter Righetti. Cronos Australia will serve as the Group’s hub for Australia, New Zealand, and South East Asia, bolstering the Group’s import/export supply capabilities and distribution network. Cronos Australia will leverage the Group’s intellectual property and iconic brands to deliver premium cannabinoid based products to Australasia.
read moreCronos Group announces appointment of Jim Rudyk, CFO of Roots, to the Board
Mr. Rudyk is currently the chief financial officer of Roots Corporation (“Roots”), a position he has held since January 2016. Mr. Rudyk is an experienced and proven financial executive with more than 25 years of financial and operational experience and a track record of supporting ambitious growth plans.
read moreCronos Group Announces Closing of Previously Announced $46 Million Bought Deal
(“Cronos Group” or the “Company”) is pleased to announce that it has closed its previously announced bought deal public offering, including the full exercise of the over-allotment option. As such, a total of 5,257,143 common shares of Cronos Group (the “Shares”) were sold at a price of $8.75 per Share for aggregate gross proceeds of approximately $46.0 million (the “Offering”).
read morePeace Naturals Receives Dealer’s License Allowing for the Exportation of New Product Categories
Cronos Group is pleased to announce that Peace Naturals Project Inc., a licensed producer wholly owned by the Company, has just obtained a Dealer’s License pursuant to the Controlled Drugs and Substances Act under Health Canada.
read moreCronos Group Inc. Announces Upsize of Previously Announced Bought Deal Financing to $40 million
Cronos Group Inc. is pleased to announce that the Company has entered into a revised agreement with a syndicate of underwriters led by PI Financial Corp., to increase the size of its previously announced bought deal financing to approximately $40 million aggregate gross proceeds, representing 4,571,429 shares of the Company, at a price of $8.75 per Share.
read moreCronos Group Inc. Announces $30 Million Bought Deal
Cronos Group Inc. is pleased to announce that it has entered into a letter of engagement with PI Financial Corp. as lead underwriter on behalf of a syndicate of underwriters under which the Underwriters have agreed to purchase for re-sale 3,428,572 common shares of the Company.
read morePeace Naturals Products Now Available Through Pohl-Boskamp in German Pharmacies
TORONTO, ON (December 27, 2017) – Cronos Group Inc. (TSX-V: MJN) (OTC – Nasdaq Int’l Designation: PRMCF) (“Cronos” or the “Company”) is pleased to announce that its first shipment to G. Pohl-Boskamp GmbH & Co. KG (“Pohl-Boskamp”) of Peace Naturals (“Peace”)...
read moreCronos Press Release – Q3 2017 Financial Results
Cronos Group today reported financial results for the third quarter ended September 30, 2017. Financial results and the management discussion and analysis are available on the Company’s website and SEDAR (www.sedar.com).
read moreCronos Group to Hold Conference Call on Q3 2017 Financial Results
Cronos Group will release its financial results for the third quarter ended September 30, 2017 before the market opens on November 29, 2017
read moreCronos Announces Exchange Approval for Cronos Israel and Key Additions to Senior Leadership Team
Cronos is pleased to announce that its previously announced strategic joint venture with Kibbutz Gan Shmuel for the production, manufacture, and global distribution of medical cannabis, has been approved by the TSX Venture Exchange.
read moreCronos Group Announces Closing of Previously Announced $17 Million Bought Deal
Cronos Group is pleased to announce that it has closed its previously announced bought deal public offering, including the full exercise of the over-allotment option.
read moreCronos Group Inc. Announces $15 Million Bought Deal
Cronos is pleased to announce that it has entered into a letter of engagement with PI Financial Corp.
read moreCronos Announces Exclusive Distribution Agreement with Pohl-Boskamp in Germany
Cronos is pleased to announce that it has entered into a strategic distribution partnership with G. Pohl-Boskamp GmbH & Co. KG (“Pohl-Boskamp”)
read more
Cronos Rebrands Recreational Platform
OGBC is located on 31 acres of land in the Okanagan Valley in British Columbia and is focused on quality and integrity, committed to continuing BC’s long history of producing some of the world’s finest cannabis
read moreCronos Announces Closing of Non-Brokered Private Placement
“We are extremely fortunate to have investors that share our vision and are focused on the long term. Our strategic capital partners add intangible value that doesn’t show up on the balance sheet,” said Mike Gorenstein, CEO of Cronos.
read moreCronos Announces Upsizing of Private Placement of Common Shares
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES TORONTO, Sept. 18, 2017 /CNW/ - Further to its press release on September 14, 2017, Cronos Group Inc. ("Cronos" or the "Company") (TSX Venture: MJN) (OTC – Nasdaq International...
read moreCronos Announces Private Placement of Common Shares
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES TORONTO, Sept. 14, 2017 /CNW/ - Cronos Group Inc. ("Cronos" or the "Company") (TSX Venture: MJN) (OTC – Nasdaq International Designation: PRMCF) is pleased to announce that it...
read moreCronos Receives Nasdaq International Designation
TORONTO, Sept. 12, 2017 /CNW/ - Cronos Group Inc. (TSXV: MJN) (OTC: PRMCF) ("Cronos" or the "Company") is pleased to announce that it is the first cannabis company to be admitted into the Nasdaq International Designation program under the symbol OTC – Nasdaq...
read moreCronos Establishes International Low Cost Production in Israel
TORONTO, Sept. 6, 2017 /CNW/ - Cronos Group Inc. (TSXV: MJN) (OTC: PRMCF) ("Cronos" or the "Company") is pleased to announce that the Company has entered into a strategic joint venture ("Cronos Israel") with Kibbutz Gan Shmuel ("Gan Shmuel") for the production,...
read moreCronos Group Announces Supply Agreement with Cannamedical Pharma in Germany
Cronos Group is pleased to announce that one of its wholly-owned licensed producers, Peace Naturals Project Inc. has entered into a supply agreement with Cannamedical Pharma GmbH.
read moreCronos Group Begins Exporting Cannabis Oil to the Cayman Islands
Peace Naturals Project Inc. has successfully completed the Company’s first shipment of medical cannabis oil to the Cayman Islands. This marks the first time Cronos has exported an extract based product.
read moreQ2 2017 Financial Results and Provides Operational Update
TORONTO, Aug. 28, 2017 /CNW/ - Cronos Group Inc. (TSXV:MJN) (OTC: PRMCF) ("Cronos" or the "Company") is pleased to report the financial results and accompanying management discussion and analysis for the quarter ending June 30, 2017; copies are available on the...
read moreCronos Group Secures $40M in Debt for Domestic Capacity Expansion
TORONTO, Aug. 24, 2017 /CNW/ – Cronos Group Inc. is announcing today that it has entered into a commitment letter for $40 million in debt financing with Romspen Investment Corporation (“Romspen”) to fund the continued construction of its 315,000 sq. ft. expansion (the “New Peace Facility”) previously outlined in the Company’s press release dated May 23, 2017.
read moreCronos Group Files Q1 2017 Financial Results
TORONTO, May 30, 2017 /CNW/ - Cronos Group Inc. (TSX VENTURE: MJN) ("Cronos" or the "Company") is pleased to report the financial results and accompanying management discussion and analysis for the quarter ending March 31, 2017; copies are available on the Company's...
read moreCronos Breaks Ground on World’s Largest Purpose-Built Indoor Cannabis Facility
The expansion includes a state-of-the-art 286,000 sq. ft. production facility, a 28,000 sq. ft. greenhouse, and an additional 1,200 sq. ft. extraction laboratory. Upon completion, the New Facility is expected to be the largest purpose-built indoor cannabis production facility in the world.
read moreCronos Group Responds to Health Canada Testing
TORONTO, May 5, 2017 /CNW/ - Cronos Group Inc.'s (TSXV:MJN) wholly owned licensed producer, the Peace Naturals Project Inc. ("Peace"), was notified on May 4, 2017 by Health Canada that upon testing a random cannabis leaf sample, trace levels of Piperonyl Butoxide...
read morePeace Naturals Awarded GMP Certification Fortifying Global Distribution
TORONTO, May 2, 2017 /CNW/ - Cronos Group Inc. (TSXV:MJN) ("Cronos" or the "Company") is pleased to announce that following a comprehensive audit, the Company's wholly owned licensed producer ("LP"), the Peace Naturals Project Inc. ("Peace"), has been issued a Good...
read moreCronos Group Provides Operational Update and Files 2016 Financial Results
TORONTO, ON--(Marketwired - May 01, 2017) Cronos Group Inc. (formerly PharmaCan Capital Corp.) (TSX VENTURE: MJN) ("Cronos" or the "Company") is pleased to report the financial results and accompanying management discussion and analysis for the year ending December...
read moreCronos Group Provides Update on Minority Investments
TORONTO, ON--(Marketwired - April 24, 2017) Cronos Group Inc. (formerly PharmaCan Capital Corp.) (TSX VENTURE: MJN) ("Cronos", or the "Company") is providing an update on its investments in Whistler Medical Marijuana Corporation ("Whistler"), The Hydropothecary...
read moreCronos Re-Invests in Whistler as Part of Transformative Expansion
Cronos Group is pleased to announce that WMMC has been granted an affirmation letter from Health Canada regarding the company’s announced 65,000 square foot expansion in Pemberton, British Columbia.
read moreCronos Group Announces Closing of Previously Announced $17 Million Bought Deal
Cronos Group is pleased to announce that it has closed its previously announced bought deal public offering.
read moreCronos Recognized as Top TSX Venture 50 Performer
TORONTO, Feb. 27, 2017 /CNW/ - Cronos Group Inc., formerly PharmaCan Capital Corp., (TSX VENTURE: MJN) ("Cronos Group" or "the Company"), is excited to announce the Company's recent recognition as the top performer in the 2017 TSX Venture 50, an award reserved for the...
read morePharmaCan Capital Announces $15 Million Bought Deal
TORONTO, ONTARIO--(Marketwired - Feb. 14, 2017) - NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE:MJN) ("Cronos" or the "Company") is pleased...
read moreCronos Calls Shareholder Meeting to Formalize Name Change
TORONTO, ON--(Marketwired - January 23, 2017) PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos" or the "Company"), seeks shareholder approval to formally change its name to "Cronos Group Inc." following the corporate...
read moreCronos Applauds German Legalization of Medical Cannabis
In a landmark bill, members of Germany’s parliament voted unanimously to legalize the use of medical marijuana and have implemented a policy that will provide health insurance coverage for patients with an eligible prescription.
read moreCronos Group Granted Second Health Canada Sales License
TORONTO, ON--(Marketwired - January 11, 2017) - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos" or the "Company"), is pleased to announce that the...
read moreCronos Enters Exclusive European Supply Agreement with Pedanios
TORONTO, ON - (Marketwired - December 28, 2016) PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos" or "the Company"), is pleased to announce the execution of an exclusive supply agreement with German-based Pedanios GmbH ("Pedanios")...
read moreCronos Embraces Legalization Task Force Report
The Cronos Group is pleased with and supportive of the recommendations provided in the report by the Task Force on Cannabis Legalization and Regulation.
read moreCronos Launches Industry Leading JV with First Nations
Indigenous Roots will work cooperatively with First Nations towards building and operating licensed facilities and providing medical cannabis to patients.
read moreCronos Group Provides Operational Update and Q3 Financial Results
TORONTO, ON –November 29, 2016 NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE PharmaCan Capital Corp., doing business as Cronos Group (TSXV:MJN) (“Cronos” or the “Company”) is pleased to provide the first operational update related to its...
read moreCronos Group Grants Stock Options
TORONTO, ONTARIO--(Marketwired - Nov. 21, 2016) - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES PharmaCan Capital Corp. doing business as Cronos Group ("Cronos Group" or the "Company") (TSX VENTURE:MJN) announces it has granted...
read moreCronos Group Enters Agreement With XIB Consulting
Cronos Group has entered an engagement agreement with XIB Consulting Inc., to assist Cronos with business management and corporate development initiatives.
read moreCronos Group Receives Liquidity From Non-Core Asset
TORONTO, ON--(Marketwired - November 01, 2016) - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos Group" or "the Company"), has divested its equity...
read moreCronos Group Closes Previously Announced Transaction to More Than Double Acreage at in the Zone Produce Ltd.’s BC Production Campus
TORONTO, ON--(Marketwired - October 24, 2016) - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos Group" or "the Company"), is pleased to announce...
read moreCronos Group Takes First Step in Global Expansion: Peace Naturals Project Exports to Germany
TORONTO, ONTARIO--(Marketwired - October 11, 2016) - TORONTO, ON--(Marketwired - October 11, 2016) - PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos Group" or "the Company") is pleased to announce that its wholly owned subsidiary,...
read morePharmaCan announces corporate rebranding to become Cronos Group
PharmaCan Capital today announced a corporate rebranding to Cronos Group. This rebranding reflects the new strategic vision of the Company as Canada’s first bi-coastal licensed cannabis producer with interests in five Licensed Producers (“LPs”) and three license applicants.
read morePharmaCan More Than Doubles Acreage at In The Zone Produce Ltd.’s BC Production Campus
PharmaCan has entered into a definitive Purchase Agreement to acquire approximately 17 acres of land adjacent to the existing campus of In the Zone Produce Ltd.
read morePharmaCan Acquires Peace Naturals Project Inc.
The acquisition of Peace Naturals immediately positions the Company as a dominant force in the Canadian cannabis market.
read moreClosing Of Second Tranche Of Non-brokered Private Placement
The proceeds of the Offering will be used for the financing by the Company of its acquisition of Peace Naturals Project Inc. and general corporate purposes.
read moreUpdate On Non-Brokered Private Placement
The proceeds of the Offering will be used for the financing by the Company of its acquisition of Peace Naturals Project Inc.
read morePharmaCan Announces Closing of First Tranche of Non-Brokered Private Placement
PharmaCan is pleased to announce the closing of the first tranche (the “First Tranche”) of the previously announced non-brokered private placement.
read morePHARMACAN CAPITAL CORP. (“MJN-V”) – Grants Stock Options
PharmaCan Capital Corp. announces it has granted options to subscribe to an aggregate of 975,000 common shares in accordance with the Company’s stock option plan.
read morePharmaCan Enters Into Share Purchase Agreement to Acquire Peace Naturals Project; Announces Proposed Private Placement of Shares
PharmaCan Capital Corp. is pleased to announce that it has entered into a share purchase agreement to acquire all of the shares of Peace Naturals Project Inc.
read morePharmaCan Strengthens Board of Directors With Addition of Jason Adler
PharmaCan Capital Corp. is pleased to announce that Mr. Jason Adler will be joining the board of directors.
read morePharmaCan Announces Tranche of Private Placement
PharmaCan is pleased to announce the closing of second and final tranche of the previously announced non-brokered private placement.
read morePharmaCan Announces Director Resignation
PharmaCan Capital Corp. Lorne Gertner has announced his resignation as a director of PharmaCan effective May 19, 2016
read morePharmaCan Announces Closing of First Tranche of Non-Brokered Private Placement and Increases Size of Offering; Michael Gorenstein Appointed as CEO
PharmaCan announces closing of first tranche and is pleased to announce the appointment of Michael Gorenstein, effective immediately.
read morePharmaCan Announces Non-Brokered Private Placement of up to $5 Million
PharmaCan Capital Corp. is pleased to announce a non-brokered private placement offering (the “Offering”) to raise up to $5,000,000.
read morePharmaCan Announces In The Zone MMPR License Renewal and Whistler Medical Marijuana MMPR License Amendment to Sell Cannabis Oil
PharmaCan Announces In The Zone MMPR License Renewal and Whistler Medical Marijuana MMPR License Amendment to Sell Cannabis Oil
read morePharmaCan Served With Statement of Claim
PharmaCan Capital Corp. has been served with a Statement of Claim filed by 2073056 Ontario Ltd in the Ontario Superior Court of Justice.
read morePharmacan Announces Restructuring of Its Board of Directors
PharmaCan is pleased to announce that it has implemented a change to its Board of Directors reducing the number of serving Board members from seven to five.
read morePharmaCan Provides Update on the Closing of Sale of Shares of Peace Naturals
PharmaCan has been advised that the proposed sale of the Barnes Family Trust’s shares in The Peace Naturals Project has been terminated.
read morePharmaCan Announces In The Zone Produce Ltd. Receives Approval for MMPR License Amendment From Health Canada
ITZ has received approval from Health Canada for its application to amend its Marihuana for Medical Purposes Regulation (“MMPR”) license.
read morePharmaCan Provides Update on the Closing of Sale of Shares of Peace Naturals
PharmaCan Capital Corp. announces that the proposed sale of the Barnes Family Trust’s shares in The Peace Naturals Project Inc., scheduled to close on December 11, 2015 did not close.
read morePharmaCan Notified of Update on the Closing of Sale of Shares of Peace Naturals
PharmaCan Capital Corp. announces that it has been provided with an update indicating the proposed sale of the Barnes Family Trust’s shares in Peace Naturals.
read morePharmaCan Announces Adoption of Shareholder Rights Plan and Changes to the Board of Directors
TORONTO, ON--(Marketwired - November 09, 2015) NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES PharmaCan Capital Corp. (TSX VENTURE: MJN) ("PharmaCan" or the "Company") announces the Board of Directors has adopted a Shareholders...
read morePharmaCan Notified of Update on the Closing of Sale of Shares of Peace Naturals
PharmaCan Capital Corp. announces that the Barnes Family Trust has provided an update that the proposed sale of its shares in Peace Naturals.
read morePhamaCan Announces Notice of Exercising Tag Along Rights to Participate in the Sale of All of Its Shares in Peace Naturals
Notice that it will participate fully in the Share Purchase Agreement that the BFT entered into for the sale of all of their shares in Peace Naturals.
read morePharmaCan Announces Additional Tranches of Non-Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES TORONTO, ON--(Marketwired - October 29, 2015) PharmaCan Capital Corp. (TSX VENTURE: MJN) ("PharmaCan" or the "Company") is pleased to announce the closing of additional tranches of...
read moreFinancial Statements
Unaudited Consolidated Financial reports and Management’s Discussion and Analysis reports for Cronos Group will be posted here quarterly. Please visit SEDAR for a complete listing of corporate filings and archived filings for Cronos Group Inc.
Financial
Statements
Unaudited Consolidated Financial reports and Management’s Discussion and Analysis reports for Cronos Group will be posted here quarterly. Please visit SEDAR for a complete listing of corporate filings and archived filings for Cronos Group Inc.
2018
2018 – Q3 Management’s Discussion and Analysis (MD&A)
2018 – Q2 Interim Condensed Financial Statements
2018 – Q2 Management’s Discussion and Analysis (MD&A)
2018 – Q1 Interim Condensed Financial Statements
2018 – Q1 Management’s Discussion and Analysis (MD&A)
2017
2017 – Q1 Management’s Discussion and Analysis (MD&A)
2017 – Q2 Interim Condensed Financial Statements
2017 – Q2 Management’s Discussion and Analysis (MD&A)
2017 – Q3 Interim Condensed Financial Statements
2017 – Q3 Management’s Discussion and Analysis (MD&A)
2017 – Annual Information Form PDF
2017 – Year End Consolidated Financial Statements PDF
2017 – Year End Management’s Discussion and Analysis (MD&A) PDF
Year End Notice of Record and Meeting Date PDF
______________________________________________
XBRL Instance Document (XML)
XBRL Taxonomy Extension Calculation Linkbase (XML)
XBRL Taxonomy Extension Definition Linkbase (XML)
XBRL Taxonomy Extension Label Linkbase (XML)
XBRL Taxonomy Extension Presentation Linkbase (XML)
XBRL Taxonomy Extension Schema (XSD)
720 King Street West, Suite 320
Toronto, Ontario M5V 2T3
Info@TheCronosGroup.com
Careers@TheCronosGroup.com
(416) 504-0004